Skip to main content

GE Healthcare to Exclusively Distribute DiscoveRx s HitHunter cAMP Assays Worldwide

NEW YORK, May 24 (GenomeWeb News) - GE Healthcare signed an exclusive distribution agreement with DiscoveRx for its HitHunter cAMP assays, GE Healthcare said today.

Terms of the deal call for GE to exclusivelty distribute DiscoveRx's HitHunter cAMP Enzyme Fragment Complementation-based assays worldwid. The deal also expands GE's rights to distribute DiscoveRx's portfolio of kinase assays, with exclusive distribution in the Asia-Pacific region.


The cAMP assays are designed for high throughput, non-radioactive screening of compounds in drug discovery. The homogeneous cell-based assays are used to screen for G-protein coupled receptor activation in a microplate-based format.

Financial details were not disclosed.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.